⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
globenewswire.com
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BMEA